Back To Top

Three times first: With the new surgical microscope with integrated intra-operative OCT ZEISS provides surgeons unprecedented views of transparent ocular structures

JENA/Germany, 17.03.2014.

The medical technology company ZEISS was the first presenting a surgical microscope and the first commercializing OCT for ophthalmic applications. By merging two gold standards into one system ZEISS again is the first introducing a surgical microscope with integrated intra-operative OCT, the OPMI LUMERA® 700 and RESCAN™ 700. It provides ophthalmic surgeons highest quality intraoperative OCT visualization of the eye within their surgical view and without interruption of surgery.

Surgeons now can see even transparent structures of the eye during surgery, monitor progress during a procedure and verify clinical results in the OR. “With the new device from ZEISS we have for the first time a complete integration of the OCT into the microscope,” says Susanne Binder MD, Professor and Chair, Department of Ophthalmology, Rudolf Foundation Clinic, Teaching Hospital of the Medical University of Vienna, who supported the development of the new device. During the Frankfurt Retina Meeting which took place on March 15 and 16, 2014, in Mainz, Germany, Prof. Ramin Tadayoni from Hôpital Lariboisière, Paris, France performed a live surgery with this newest addition to ZEISS’ surgical device range.

Today surgeons may have difficulties seeing certain anatomic details during surgery. With its new visualization tool Medical technology business group of ZEISS aims for overcoming these limits . “It is amazing - you suddenly see things that you have never seen before”, says Prof. Oliver Findl, MD, MBA from the Hanusch Hospital in Vienna, Austria. “For me, the new device from ZEISS is something I really wouldn’t want to miss anymore”.

ZEISS HD-OCT images add a real time third dimension to the visualization capabilities directly in the eyepiece It provides surgeons with unprecedented views below the surface of the surgical field enabling them to see more, even transparent structures in the anterior and posterior segment of the eye.

ZEISS RESCAN 700 and CALLISTO eye® help surgeons to concentrate more on the surgical procedure as the necessary structural information known from pre-operative OCTs is available all the time intraoperatively. Additionally, the continuous OCT scanning supports achieving better patient outcomes as the surgeon can monitor progress and verify results during the procedure.

OCT scans can also be stored and recalled for later review and “fly through” via CALLISTO eye from ZEISS. That way the new device enables better decision making during surgery. “I now have a lot of new information that helps me to decide whether my presurgical approach is the right one or whether I have to change my approach during the procedure,” says Marta S Figueroa, MD, PhD from the Hospital Universitario Ramón y Cajal, Madrid, Spain. Prof. Findl even re-assessed his surgical technique: “With ZEISS OPMI LUMERA 700 and RESCAN 700 we learn a lot of things to enhance our own performance.”

ZEISS RESCAN 700 is useful for various surgeries in the anterior and posterior segment of the eye with a broad range of potential applications. “The first positive experiences surgeons made with our new intra-operative OCT confirmed our approach to merge two of our gold standards into one system. By doing this we now are able to support our customers even better to improve patient outcomes. The possibilities of how this new visualization technology will change ophthalmic surgery and expand the capabilities especially for retina and cornea surgeons are now just beginning to be realized,” says Dr. Ludwin Monz, President and CEO Carl Zeiss Meditec AG.

 

 

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials. The company creates innovative visualisation solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In financial year 2012/2013 (ended 30 September) the Group's more than 2,500 employees generated revenue of almost € 906 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries. Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.

We use cookies on this site. Cookies are small text files that are stored on your computer by websites. Cookies are widely used and help to optimize the pages that you view. By using this site, you agree to their use. more

OK